CareLit · DOI-Nachweis · Zeitschrift für Gastroenterologie
CPT11/FA/5-FU versus ELF in chemonaive patients with advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction: a randomized phase II study of the AGO
DOI 10.1055/s-2004-831410
Bibliografische Angaben
Nachweis in CareLit
Autor:innenM Möhler, J Siebler, T Höhler, J Janssen, A Wein, M Menges, D Flieger, T Junginger, PR Galle, M Heike
ZeitschriftZeitschrift für Gastroenterologie
Ausgabe08/2004
Jahrgang / SeitenNicht angegeben
Kernaussage aus der Literatur
Abstract-Vorschau
Aims: Combinations of irinotecan (CPT11) with continuous folinic acid (FA) and 5-fluorouracil (5-FU) have shown promising activity in advanced or metastatic gastric cancer (AGC). We prospectively evaluated toxicity, efficacy and survival of CPT11/FA/5-FU (arm A) versus Etoposide/FA/5-FU (ELF; arm B) in AGC. As ELF was not inferior to FAMTX or Cisplatin/5-FU in a recent EORTC trial, ELF served as control arm. Methods…
Zitieren
Zitierempfehlung
M Möhler, J Siebler, T Höhler, J Janssen, A Wein, M Menges, D Flieger, T Junginger, PR Galle, M Heike (2004) CPT11/FA/5-FU versus ELF in chemonaive patients with advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction: a randomized phase II study of the AGO. Zeitschrift für Gastroenterologie (08). https://doi.org/10.1055/s-2004-831410
Mit CareLit weiterarbeiten